Meta-analysis: Oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 6, 2012, Pages 674-689

  Singal, A K ^a   Fontana, R J ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; TELBIVUDINE; TENOFOVIR;

ALCOHOL ABUSE; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; KIDNEY FAILURE; LIMIT OF DETECTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; META ANALYSIS; MIXED INFECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEROCONVERSION; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857368529     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04990.x     Document Type: Article

References (48)

1. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Chu CM, Liaw YF,. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693-9.
3. Belongia EA, Costa J, Gareen IF, et al,. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008; 25: 1-29.
4. de Jongh FE, Janssen HL, de Man RA, et al,. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
5. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
6. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
7. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
8. Liaw YF, Sung JY, Chow CC, et al,. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003; 38 (Suppl. S4): 262A.
9. Perrillo R, Tamburro C, Regenstein F, et al,. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
10. Jadad AR, Moore RA, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
11. von Elm E, Altman DG, Egger M, et al,. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
12. Villeneuve JP, Condreay LD, Willems B, et al,. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
13. Yao FY, Bass NM,. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7.
14. Perrillo RP, Wright T, Rakela J, et al,. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-32.
15. Fontana RJ, Keeffe EB, Carey W, et al,. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433-9.
16. Andreone P, Biselli M, Gramenzi A, et al,. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002; 74: 1119-24.
17. Hann HW, Fontana RJ, Wright T, et al,. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49-56.
18. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al,. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63.
19. Nikolaidis N, Vassiliadis T, Giouleme O, et al,. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005; 19: 321-6.
20. Tseng P, Lu SN, Tung HD, et al,. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386-92.
21. Wong SN, Reddy KR, Keeffe EB, et al,. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007; 13: 334-42.
22. Osborn MK, Han SH, Regev A, et al,. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007; 5: 1454-61.
23. Nishida T, Kobashi H, Fujioka S, et al,. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 2008; 23: 794-803.
24. Kao JTPC, Lai HC, Chuang PH, et al,. Efficcay of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis. J Gastrotroenterol Hepatol 2009; 24: A202.
25. Gane EC, Chan HL, Choudhuri G, et al,. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52: S1-21.
26. Kim KM, Choi WB, Lim YS, et al,. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci 2005; 20: 821-8.
27. Liaw YF, Lee CM, Chien RN, et al,. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006; 13: 250-5.
28. Schiff E, Lai CL, Hadziyannis S, et al,. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.
29. Zoulim F, Parvaz P, Marcellin P, et al,. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009; 29: 420-6.
30. Liaw YS, Raptopoulou-Gigi M, Cheinquer H, et al,. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: randomized, open-label study. Hepatology 2011a; 54: 91-100.
31. Liaw YS, Sheen IS, Lee CM, et al,. Tenofovir disproxil fumarate (TDF), emtricitabine/TDF and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease. Hepatology 2011b; 53: 62-72.
32. Pellicelli AM, Barbarini G, Romano M, et al,. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral and biochemical outcomes at one year. Hepatology 2009; 50: 514A.
33. Shim JH, Lee HC, Kim KM, et al,. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-82.
34. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
35. Kamath PS, Wiesner RH, Malinchoc M, et al,. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
36. Woo G, Tomlinson G, Nishikawa Y, et al,. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
37. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
38. Tenney DJ, Rose RE, Baldick CJ, et al,. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
39. Fleischer RD, Lok AS,. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51: 787-91.
40. van Bommel F, Wunsche T, Mauss S, et al,. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
41. Berg T, Marcellin P, Zoulim F, et al,. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207-17.
42. Raijnders JG, Vries-Sluijs T, Hansen BE, et al,. Five-year tenofovir therapy is asssociated with maintained virologic response but significant decline in renal function in HIV-HBV coinfected patients. Hepatology 2009; 50: 506A.
43. Rodriguez -Novoa S, Alvarez E, Labarga P, et al,. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9: 545-59.
44. Fontana RJ,. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-95.
45. Fontana RJ,. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010; 52: 147-9.
46. Lange CM, Bojunga J, Hofmann WP, et al,. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-6.
47. Schiff E, Simsek H, Lee WM, et al,. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-83.
48. Boxer AP, Protano MA, Vachon MC, et al,. Telbivudine elevations of CPK in chronic hepatitis B patients in a clinical setting. Hepatology 2010; 52: 533A.